X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New comments outline ways to counteract cost-shifting insurance trends

By Ashley Czin  |    January 28, 2022
PhRMA submitted comments this week in response to the Department of Health & Human Services’ (HHS) 2023 Notice of Benefit and Payment Parameters (NBPP) proposed rule. As outlined in our comments,...   Read More

New study finds more than half of brand medicine spending goes to the supply chain and others

By Brian Newell  |    January 7, 2022
More than half of total spending on brand medicines went to the supply chain, middlemen and other stakeholders in 2020 according to a new analysis from the Berkeley Research Group (BRG). These new...   Read More

Making medicines more affordable: Preserving safety-net programs like 340B

By Emilie Signora  |    December 17, 2021
Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s advocacy...   Read More

Post-approval research save lives. Why is Congress trying disincentivize it?

By Andrew Powaleny  |    December 17, 2021
While some in Congress continue to claim the latest drug pricing plan in Washington is “negotiation,” that is far from the truth. The reality is that the current plan gives the government a new...   Read More

A price control by any other name would still put patients at risk and threaten innovation

By Nicole Longo  |    December 9, 2021
Some policymakers in DC are laser focused on giving the government the power to “negotiate” in Medicare. What they aren’t saying is that this isn’t negotiation at all. They essentially just want the...   Read More

Making medicines more affordable: Making insurance work like insurance

By Emilie Signora  |    December 8, 2021
Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s advocacy...   Read More

Navigating the patient experience in the time of COVID-19

By Cynthia Hicks  |    December 6, 2021
According to our inaugural Patient Experience Survey, the pandemic has created new access and affordability barriers to care, exacerbating the health care concerns of Americans and their families. ...   Read More

New poll shows Americans reject Medicare negotiation once they learn more about the policy

By Cynthia Hicks  |    October 15, 2021
As the debate in Washington around drug pricing proposals continues to intensify, a new Ipsos/PhRMA poll shows Medicare “negotiation” is not nearly as popular as some might suggest. Survey findings...   Read More

New report shows 3 in 10 Americans that have insurance still face a financial barrier to care

By Katie Koziara  |    October 7, 2021
Today, we released the results in the first report in a series on patient experiences with the health care system. The report, titled “Barriers to Health Care Access in the Patient Experience,”...   Read More

PhRMA releases 2021 industry profile

By Gabby Migliara  |    September 20, 2021
Today, PhRMA released its 2021 Biopharmaceutical Industry Profile, a resource that highlights the latest from the industry on innovation, access and affordability. The Profile has told the story of...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates